Evotec SE (NASDAQ:EVO - Get Free Report) shares saw unusually-high trading volume on Thursday . Approximately 338,948 shares changed hands during mid-day trading, an increase of 208% from the previous session's volume of 110,085 shares.The stock last traded at $5.31 and had previously closed at $5.25.
Analyst Upgrades and Downgrades
EVO has been the subject of several analyst reports. Royal Bank of Canada raised Evotec from a "sector perform" rating to an "outperform" rating in a report on Thursday, January 18th. HC Wainwright decreased their price objective on Evotec from $14.00 to $11.00 and set a "buy" rating for the company in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised Evotec from a "hold" rating to a "buy" rating in a report on Friday, April 12th.
Check Out Our Latest Analysis on Evotec
Evotec Stock Up 2.3 %
The business has a fifty day moving average of $7.07 and a two-hundred day moving average of $8.51.
Hedge Funds Weigh In On Evotec
A number of large investors have recently bought and sold shares of the business. Mubadala Investment Co PJSC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $53,931,000. Optiver Holding B.V. raised its holdings in shares of Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock valued at $945,000 after acquiring an additional 69,936 shares during the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $25,000. Institutional investors and hedge funds own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
